- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01030601
Analysis of the Effect of Intravitreal Dexamethasone Injection on Diabetic Macular Edema After Cataract Surgery (IDDMECS) (IDDMECS)
Macular Edema (Swelling of a particular site of the retina) can become a significant problem for Diabetics undergoing Cataract surgery. And a significant number of people who undergo Cataract surgery each year are diabetics. And when you multiply these two factors together you are left with a significant number of people who do not gain as much vision as their peers. Diabetics who develop Macular Edema actually can loose some vision after surgery and when you follow them up, they don't gain as much vision. This Study aims to prevent such an event from happening and therefore allow Diabetics to gain as much vision as they can from cataract surgery. This study will use Dexamethasone injected intravitreally (into the gel of the eye) at the end of cataract extraction to control Macular edema brought about by surgery. The main outcome is the central retina thickness and retinal volume as measured by Optical Coherence Tomography. Secondary outcomes are BCVA and incidence of Laser Treatment.
Other Drugs, life Bevacizumab and Pegaptanib, have been used for this purpose but they are expensive and have potential systemic side-effects due to anti-VEGF (vascular endothelial growth factor) actions. Dexamethasone has been used in the eye for decades and is short-lived, minimizing possible systemic effects. Moreover, this drug is at least 15x cheaper than the previously mentioned ones and therefore has tremendous benefit for developing countries. We seek an alternative drug that can reduce or prevent Macular edema at a less expensive and safer way.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Forventet)
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
Ontario
-
Toronto, Ontario, Canada, M5T 2S8
- Toronto Western Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Diabetic patients for Cataract Surgery with vision of ≤ 20/50 and > grade 3 any cataract type using the Lens Opacities Classification System III. Diabetics included must have at least one microaneurysm in the posterior pole (defined by the Superior and Inferior Arcade).
Exclusion Criteria:
- Without any diabetic retinopathy and those with active uncontrolled proliferative disease
- Retinal disease,other than Diabetes, that can affect macular edema
- Uveitis, a history of any other intraocular surgery or a history of uncontrolled glaucoma
- Eyes with cataract precluding proper OCT measurement pre-operatively
- Patients who will experience longer than usual operating time, complicated surgery, rupture of the posterior capsule, and iris or corneal burns
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Ingen indgriben: Control
Diabetics undergoing routine cataract surgery
|
|
|
Eksperimentel: Treatment
Diabetics undergoing cataract surgery with injection of 0.5mg in 0.05cc of dexamethasone at the end of surgery
|
0.5mg in 0.05cc of Dexamethasone from a 10mg/ml vial
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Central Retinal Thickness
Tidsramme: within 3 months after cataract surgery
|
within 3 months after cataract surgery
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Best corrected visual acuity and incidence of laser treatments
Tidsramme: within 3 months after cataract surgery
|
within 3 months after cataract surgery
|
Samarbejdspartnere og efterforskere
Efterforskere
- Ledende efterforsker: Michael H Brent, MD, FRCSC, University Health Network, Toronto
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Øjensygdomme
- Nethindedegeneration
- Nethindesygdomme
- Makuladegeneration
- Linsesygdomme
- Makulaødem
- Grå stær
- Ødem
- Kapselopacificering
- Pseudofaki
- Lægemidlers fysiologiske virkninger
- Molekylære mekanismer for farmakologisk virkning
- Autonome agenter
- Agenter fra det perifere nervesystem
- Enzymhæmmere
- Anti-inflammatoriske midler
- Antineoplastiske midler
- Antiemetika
- Gastrointestinale midler
- Glukokortikoider
- Hormoner
- Hormoner, hormonsubstitutter og hormonantagonister
- Antineoplastiske midler, hormonelle
- Proteasehæmmere
- Dexamethason
- Dexamethasonacetat
- BB 1101
- Dexamethason 21-phosphat
Andre undersøgelses-id-numre
- IDDMECS
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Dexamethasone sodium phosphate
-
Semnur Pharmaceuticals, Inc.Cromos Pharma LLC; SyngeneIkke rekrutterer endnuLumbosakral radikulær smerte
-
TheiaNova Ltd.Tilmelding efter invitation
-
Southeast University, ChinaIkke rekrutterer endnuAkut Respiratory Distress Syndrome (ARDS)Kina
-
Mercator MedSystems, Inc.AfsluttetPerifere arterielle sygdommeForenede Stater
-
Aciont IncNational Eye Institute (NEI)AfsluttetIkke-infektiøs anterior uveitisForenede Stater
-
Poznan University of Medical SciencesIkke rekrutterer endnu
-
Irfan ÜstündağAfsluttetPostoperativ smertekontrol | Postoperativt ødem og smerter | Påvirket mandibular tredje molar ekstraktionTyrkiet (Türkiye)
-
Dompé Farmaceutici S.p.ARekrutteringAtopisk keratokonjunktivitisSpanien, Italien, Forenede Stater
-
Qianfoshan HospitalIkke rekrutterer endnuMyokardieskade | Hypokaliæmi | Hyperkaliæmi | Kronisk nyresygdom ved hæmodialyse
-
Quince Therapeutics S.p.A.BiotrialAfsluttetAtaxia TelangiectasiaDet Forenede Kongerige, Forenede Stater, Danmark, Tyskland, Italien, Norge, Polen, Spanien, Schweiz